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on day 112. One recipient is pregnant 9 months post transplant.
In summary, this regimen is well tolerated, without increased
TRM or GVHD, and supports engraftment with varied stem cell
sources despite risk factors for graft rejection. Lymphopenia in the
early post transplant period requires close vigilance and early
intervention for infection.
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FREQUENCY AND MAGNITUDE OF DOSE ADJUSTMENT OF IV BUSULFAN
IN TARGETED DOSING STRATEGY FOR PEDIATRIC ALLOGENEIC
TRANSPLANTATION
Grimley, M.S., Taylor, C., Wall, D.A. Texas Transplant Institute, San
Antonio, TX
Busulfan is an important therapuetic agent in pediatric allogeneic
transplantation. The recent introduction of IV busulfan (IV
Busulfex®, ESPpharma) has descreased the intra-and interpatient
dose variations associated with oral absorption and allows for
targeted therapy. Children have increased drug clearance and vary-
ing degrees of hepatic function both developmentally and associ-
ated with the underlying disorders for which they are being
treated. Because of this variability, ﬁrst dose pharmacokinetics
were perfomed on all of our patients to ensure the targeted AUC
was achieved. In a series of 85 consecutive children undergoing
allogeneic transplant at Methodist Children’s Hospital/Texas
Transplant Institute from June 2001 to October 2003, 45 children
received myeloablative doses of busulfan (0.8 mg/kg for patients
3-10 kgs; 1 mg/kg for patients 10 kgs till age 4 yrs; 0.8 mg/kg for
patients  4 yrs given every 6 hours for 16 doses) as part of a
busulfan/cyclophosphamide, busulfan/melphalan or busulfan/ﬂu-
darabine preparative regimen. 42/45 patients had their actual
weight used for dosing calculations. Adjusted IBW was used in 3
patients. All patients received dilantin for seizure prophylaxis. First
dose pharmcokinetics were performed by the Clinical Pharmoki-
netics Lab at Seattle Cancer Care Alliance, targetting an AUC of
900-1300 umol.min, with dose adjustments done starting with dose
7, if needed. Donor source was matched sibling donor bone mar-
row or cord blood in 10 and unrelated donor sources in 35 (2
marrow and 33 mismatched umbilical cord units). The median age
was 4.7 yrs (range 1 month to 17 years). Patients underwent
transplant for a variety of conditions: 12 AML, 5 CML, 1 JMML,
9 ALL, 1 lymphoma, 3 HLH, 10 primary immunodeﬁencies, 4
hematology disorders. No patients developed VOD. 32/33 patients
of patients who received a fully myeloabalative preparative regimen
engrafted. A targeted AUC (900-1300 umoles.min) was achieved
with initial dosing in 50% of the patients. However, many children
required dose adjustment to achieve the targeted AUC, mostly
dose escalation (see table). Given the variability of metabolism in
children, ﬁrst dose pharmacokintics are recommended. Addition-
ally, the starting dose in infants is lower than the currently recom-
mended dose.
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LARGE VOLUME LEUKAPHERESIS FOR AUTOLOGOUS PERIPHERAL
BLOOD STEM CELL COLLECTION IN CHILDREN WEIGHTING LESS THAN
25 KG
Ginani, V.C.1, Cecyn, K.Z.2, Carvalho, M.L.2, Caram, E.1, Macedo,
C.R.P.D.1, Gordan, L.N.1, Gouveia, R.V.1, Bastos, E.M.S.C.1, Del-
buono, E.1, Lee, M.L.M.1, Oliveira, O.M.W.1, Vieira, M.J.1, Seixas,
M.T.3, Petrilli, A.S.1, Seber, A.1 1. Pediatric Oncology Institute-
GRAACC-UNIFESP, Sao Paulo, SP, Brazil; 2. Hematology and He-
matotherapy-UNIFESP, Sao Paulo, SP, Brazil; 3. Pathology Depart-
ment-UNIFESP, Sao Paulo, SP, Brazil
Peripheral blood stem cells (PBSC) are the most frequent source
of hematopoietic stem cells used to rescue patients from high-dose
chemotherapy. The theoretical advantages of PBSC collections are
decreased tumor contamination and faster hematological engraft-
ment after the transplant. Small children are usually not eligible for
such protocols due to little experience of most Hematotherapy
teams, poor venous access and concern with a large extracorporeal
volume. In large volume leukapheresis (LVL) three or more blood
volumes are processed in the same procedure. LVL is also war-
ranted in pediatric patients to decrease the number of procedures
and potentially decrease tumor contamination. Twenty-ﬁve pa-
tients underwent LVL using a Cobe Spectra® cell separator be-
tween 2000-2003. All had the circuit primed with irradiated, ﬁl-
tered and resuspended red blood cells. All patients needed a central
venous catheter placed for the procedure. During the procedure,
the patients received continuous IV infusion with 10% calcium
gluconate 2cc/kg, 10% magnesium sulfate 1 cc/kg, 19.1% potas-
sium chloride 0.3 mEq/kg/hr over four hours to decrease the
adverse effects of ADC infusion. They had vital signs, EKG and
O2 saturation continuously monitored. Patients were 13M:12F
with a median age of 3.5 years-of-age (1-10). The median weight
was 14 kg (8-24). Underlying diagnoses were neuroblastoma (21),
germ cell tumors (2), non-Hodgkin’s lymphoma (1) and alveolar
soft tissue sarcoma (1). The median number of procedures was 2
(1-4). The median total nucleated cell count/kg was 16 (5-66) and
CD34/kg 6 (0.6-71). In conclusion, LVL can be safely performed
in small children if vital signs are adequately monitored and elec-
trolytes are replaced and promptly corrected.
212
AUTOLOGOUS STEM CELL TRANSPLANTATION FOR THE TREATMENT
OF PEDIATRIC SOLID TUMORS IN BRAZIL
Castro, C.G.1, Seber, A.2, Mendes, W.3, Castro, H.C.4, Borsato, M.L.4,
Gregianin, L.J.1, Ginani, V.C.2, Barros, J.C.A.4, Petrilli, A.S.2, Bru-
netto, A.L.1 1. Pediatric Oncology Unit-Hospital de Clinicas, Porto
Alegre, RS, Brazil; 2. Pediatric Oncology Institute-GRAACC-
UNIFESP, Sao Paulo, SP, Brazil; 3. Department of Pediatrics-Hospital
A.C. Camargo, Sao Paulo, SP, Brazil; 4. Pediatric Hematology and
Bone Marrow Transplantation Unit-Santa Casa de Sao Paulo, Sao
Paulo, SP, Brazil
High-dose chemotherapy and autologous stem cell rescue can be
used in the treatment of poor prognosis responsive pediatric solid
tumors. Our objective is to describe the experience of four Brazil-
ian hematopoietic stem cell transplantation (HSCT) centers in
Table.
Disease
Age
(years) Source
Cell
dose
(TNC/kg)
Engraft-
ment GVHD
Hurler’s 1.5 BM 3.26  10 (8) donor 0
Langerhan’s 19 S BM 3.38  10 (8) donor Gr1-sk
Thalassemia 10 S BM 2.2  10 (8) BM-d;PB-
mixed
0
Evan’s 12 UCB4/6 1.3  10 (7) donor 0
Aplastic anemia 12 S PB 1.9  10 (10) donor Gr1-sk
Adrenoleukodystrophy 3 S PB 4.58  10 (8) donor 0
Sickle cell anemia 2 S BM 3.3  10 (8) donor 0
Aplastic anemia 20 S BM
5/6
4.2  10 (8) NA 0
Hemophagocytosis 3 S BM 3.7  10 (8) NA 0
Aplastic anemia 32 UCB5/6 2.02  10 (7) NA 0
sk  skin; s  sibling; d  donor; NA  Not available.
Table.
Age/
Weight
Starting
Dose
(mg/kg)
AUC
mol  min:
Median
(range)
Final
Dosing
(mg/kg):
Median
(range)
Percent of
Patients
Requiring
Dose
Adjustment
Dose
Increased/
Dose
Decreased
3-10 kg
(n  12) 0.8 1167 (825-1869) 0.93 (0.67-1.25) 50%-6/12 pts 41/22
10 kg-4 years
(n  11) 1 1142 (908-1518) 1 (0.76-1.25) 27%-3/11 21/12
>4 years
(n  22) 0.8 1089 (620-1827) 0.82 (0.57-1.25) 65%-15/23 111/42
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